帕金森病外科治疗研究进展

摘要/Abstract

摘要： 帕金森病是以运动障碍为主要表现的神经退行性疾病,药物治疗以缓解运动症状为核心。外科治疗始于立体定向技术的应用,以核团毁损术与脑深部电刺激术为主要术式。帕金森病外科治疗可以部分改善临床症状,但不能延缓疾病进展。目前基于神经营养因子及神经递质替代的基因治疗方法正在研究中,它可能是帕金森病治疗较有前景的治疗方案。该文就帕金森病脑深部电刺激术及基因治疗的研究进展予以综述。

关键词: 帕金森病, 核团毁损术, 脑深部电刺激术, 基因治疗, 神经营养因子

Abstract: Parkinson’s disease(PD) is a neurodegenerative disease and its main manifestation is movement disorders.The treatment of PD focuses on the improvement of motor symptoms.With the invention of stereotactic techniques,surgical technique for PD emerged and developed,especially the technique of derogation under stereotactic orientation and the technique of deep brain stimulation.Stereotactic intervention could partially improve patient’s symptoms,but couldn’t defered the progression of PD.Gene therapy with neurotrophic factors or neurotransmitter may be a potential treatment.This article reviews the progress of deep brain stimulation surgery and gene therapy of Parkinson’s disease.

Key words: Parkinson’s Disease, Derogation, Deep brain stimulation, Gene therapy, Neurotrophic factors

中图分类号:

R651

帅松岳(综述), 靳令经(审校). 帕金森病外科治疗研究进展[J]. 外科研究与新技术, 2014, 3(1): 65-68.

SHUAI Song-yue, JIN Ling-jing. Progress of surgical treatment for Parkinson’s disease[J]. Surgical Research and New Technique, 2014, 3(1): 65-68.

参考文献

[1] Meyers R.Surgical experiments in the therapy of certain ’extrapyramidal’ diseases:a current evaluation[J].Acta Psychiatr Neurol Suppl,1951,67(1):1-42.
[2] Spiegel EA,Wycis HT,Marks M,et al.Stereotaxic Apparatus for Operations on the Human Brain[J].Science,1947,106(2754):349-350.
[3] Benabid AL,Pollak P,Gervason C,et al.Long-term suppression of tremor by chronic stimulation of the ventral intermediate thalamic nucleus[J].Lancet,1991,337(8738):403-406.
[4] Rehncrona S,Johnels B,Widner H,et al.Long-term efficacy of thalamic deep brain stimulation for tremor:double-blind assessments[J].Mov Disord,2003,18(2):163-170.
[5] Limousin P,Pollak P,Benazzouz A,et al.Effect of parkinsonian signs and symptoms of bilateral subthalamic nucleus stimulation[J].Lancet,1995,345(8942):91-95.
[6] Siegfried J,Lippitz B.Bilateral chronic electrostimulation of ventroposterolateral pallidum:a new therapeutic approach for alleviating all parkinsonian symptoms[J].Neurosurgery,1994,35(6):1126-1130.
[7] Spiegel J,Fuss G,Backens M,et al.Transient dystonia following magnetic resonance imaging in a patient with deep brain stimulation electrodes for the treatment of Parkinson disease.Case report[J].J Neurosurg,2003,99(4):772-774.
[8] Evidente VG,Premkumar AP,Adler CH,et al.Medication dose reductions after pallidal versus subthalamic stimulation in patients with Parkinson’s disease[J].Acta Neurol Scand,2011,124(3):211-214.
[9] Kleiner-Fisman G,Herzog J,Fisman DN,et al.Subthalamic nucleus deep brain stimulation:summary and meta-analysis of outcomes[J].Mov Disord,2006,21(Suppl) 14:290-304.
[10] Odekerken VJ,van Laar T,Staal MJ,et al.Subthalamic nucleus versus globus pallidus bilateral deep brain stimulation for advanced Parkinson’s disease (NSTAPS study):a randomised controlled trial[J].Lancet Neurol,2013,12(1):37-44.
[11] Sako W,Miyazaki Y,Izumi Y,et al.Which target is best for patients with Parkinson’s disease? A meta-analysis of pallidal and subthalamic stimulation[J].J Neurol Neurosurg Psychiatry,2014,Jan 20.doi:10.1136/jnnp-2013-306090.(Epub ahead of print).
[12] Eusebio A,Chen CC,Lu CS,et al.Effects of low-frequency stimulation of the subthalamic nucleus on movement in Parkinson’s disease[J].Exp Neurol,2008,209(1):125-130.
[13] Tan H,Pogosyan A,Anzak A,et al.Frequency specific activity in subthalamic nucleus correlates with hand bradykinesia in Parkinson’s disease[J].Exp Neurol,2013,240(1):122-129.
[14] Khoo HM,Kishima H,Hosomi K,et al.Low-frequency subthalamic nucleus stimulation in Parkinson’s disease:A randomized clinical trial[J].Mov Disord,2014,29(2):270-274.
[15] Ricchi V,Zibetti M,Angrisano S,et al.Transient effects of 80 Hz stimulation on gait in STN DBS treated PD patients:a 15 months follow-up study[J].Brain Stimul,2012,5(3):388-392.
[16] Schuepbach WM,Rau J,Knudsen K,et al.Neurostimulation for Parkinson’s disease with early motor complications[J].N Engl J Med,2013,368(7):610-622.
[17] Kahn E,D’Haese PF,Dawant B,et al.Deep brain stimulation in early stage Parkinson’s disease:operative experience from a prospective randomised clinical trial[J].J Neurol Neurosurg Psychiatry,2012,83(2):164-170.
[18] Benabid AL,Chabardes S,Mitrofanis J,et al.Deep brain stimulation of the subthalamic nucleus for the treatment of Parkinson’s disease[J].Lancet Neurol,2009,8(1):67-81.
[19] Rizzone MG,Fasano A,Daniele A,et al.Long-term outcome of subthalamic nucleus DBS in Parkinson’s disease:From the advanced phase towards the late stage of the disease? [J] Parkinsonism Relat Disord,2014,20(4):376-381.
[20] Lilleeng B,Bronnick K,Toft M,et al.Progression and survival in Parkinson’s disease with subthalamic nucleus stimulation[J].Acta Neurol Scand,2014,Feb 4.doi:10:1111/ane.12224.(Epub ahead of print).
[21] Vedam-Mai V,Gardner B,Okun MS,et al.Increased precursor cell proliferation after deep brain stimulation for Parkinson’s disease:a human study[J].PLoS One,2014,9(3):e88770.
[22] He Z,Jiang Y,Xu H,et al.High frequency stimulation of subthalamic nucleus results in behavioral recovery by increasing striatal dopamine release in 6-hydroxydopamine lesioned rat[J].Behav Brain Res,2014,263(1):108-114.
[23] Emborg ME,Carbon M,Holden JE,et al.Subthalamic glutamic acid decarboxylase gene therapy:changes in motor function and cortical metabolism[J].J Cereb Blood Flow Metab,2007,27(3):501-509.
[24] LeWitt PA,Rezai AR,Leehey MA,et al.AAV2-GAD gene therapy for advanced Parkinson’s disease:a double-blind,sham-surgery controlled,randomised trial[J].Lancet Neurol,2011,10(4):309-319.
[25] Christine CW,Starr PA,Larson PS,et al.Safety and tolerability of putaminal AADC gene therapy for Parkinson disease[J].Neurology,2009,73(20):1662-1669.
[26] Muramatsu S,Fujimoto K,Kato S,et al.A phase I study of aromatic L-amino acid decarboxylase gene therapy for Parkinson’s disease[J].Mol Ther,2010,18(9):1731-1735.
[27] Horger BA,Nishimura MC,Armanini MP,et al.Neurturin exerts potent actions on survival and function of midbrain dopaminergic neurons[J].J Neurosci,1998,18(13):4929-4937.
[28] Kordower JH,Herzog CD,Dass B,et al.Delivery of neurturin by AAV2 (CERE-120)-mediated gene transfer provides structural and functional neuroprotection and neurorestoration in MPTP-treated monkeys[J].Ann Neurol,2006,60(6):706-715.
[29] Marks WJ,Jr.,Bartus RT,Siffert J,et al.Gene delivery of AAV2-neurturin for Parkinson’s disease:a double-blind,randomised,controlled trial[J].Lancet Neurol,2010,9(12):1164-1172.
[30] Kordower JH,Emborg ME,Bloch J,et al.Neurodegeneration prevented by lentiviral vector delivery of GDNF in primate models of Parkinson’s disease[J].Science,2000,290(5492):767-773.
[31] Jarraya B,Boulet S,Ralph GS,et al.Dopamine gene therapy for Parkinson’s disease in a nonhuman primate without associated dyskinesia[J].Sci Transl Med,2009,1(2):2-4.